Propanc Biopharma has announced a partnership with Hexstone Capital to secure up to $100 million in funding. The funds will be used to establish a crypto treasury and advance the company's cancer therapy research. This strategic move, revealed on November 10, 2025, aims to enhance institutional interest in digital assets such as Ethereum, Bitcoin, Solana, and Injective. CEO James Nathanielsz highlighted that the capital will support a transformative phase for Propanc's proenzyme therapy platform. The collaboration with Hexstone Capital, known for its digital asset expertise, is expected to bolster Propanc's financial standing and research capabilities. The funding is structured off-chain, with no immediate crypto inflow reported.